Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Chardan Capital
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24.00 price objective on the stock. A number of other equities analysts have also recently issued reports on STOK. HC Wainwright increased their price target […]
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24.00 price objective on the stock. A number of other equities analysts have also recently issued reports on STOK. HC Wainwright increased their price target […]
